Note: Descriptions are shown in the official language in which they were submitted.
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
METHODS FOR ANTI-TUMOR THERAPY
CA 02362917 2002-08-07
,
Background of the Invention
Approximately twenty percent of deaths from all causes in the United States
are
cancer-related. Although chemotherapy is a principal means of cancer
treatment, the
rate at which effective new drugs have become available for use in cancer
chemotherapy has not increased (Horowitz et al., Journal of Clinical Oncology,
Vol. 6,
No. 2, pp. 308-314 (1988)). Despite many years of promising new therapies,
cancer
remains a major cause of morbidity and mortality (Bailar et al., N. Engl. J.
Med.
336:1569-1574, 1997). Accordingly, there is a substantial need for new drugs
which are
2o effective in inhibiting the growth of tumors.
Cardiac glycosides are potent and highly selective inhibitors of the active
transport of Na+ and K+ across cell membranes and act by binding to the alpha
subunit
of the Na+ K+-ATPase. The affinity of the alpha subunit for cardiac glycosides
varies
among species and among the three known mammalian alpha subunit isofornis,
each of
which is encoded by a separate gene. (Goodman and Gilman, "The Pharmacological
Basis of Therapeutics, 9'" edition, Hardman and Limbird eds, p. 810 (1996)).
These
compounds share a steroid nucleus containing an unsaturated lactone ring at
the C17
position and one or more glycosidic residues at C3, and occur naturally in
many plants
and several toad species, usually acting as venoms or toxins that serve as
protection
3o against predators. (Id).
2
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
Cardiac glycosides have been used extensively as therapeutics in the treatment
of heart failure. (Goodman and Gilman, "The Pharmacological Basis of
Therapeutics,
9t~' edition, Hardman and Limbird eds, p. 810 (1996)). Digitoxin has been the
most
widely used cardiac glycoside, with a therapeutic plasma concentration of
greater than
10 ng/ml (approximately 13 nM). However, digitoxin is toxic at concentrations
of
above 35 ng/ml (approximately 46 nM) (Id. at 1736). Thus, the therapeutic
window for
digitoxin in the treatment of heart failure is quite narrow.
Cardiac glycosides have also been shown to inhibit cell proliferation in a
wide
variety of cell lines in vitro. (See for example Kaneda et al., Planta Med.
58:429-431
(1992), Gil et al., J. Natural Products 58:848-856 (1995), Kitinaka et al.,
Chem. Pharm.
Bull. 44(3):615-617 (1996), Baek et al., Planta Med. 60(1):26-29 (1994), Zhang
et al.,
Chinese Medical Journal 109(6):478-481 (1996), Shiratori, GANN 58:521-528
(1967),
Doskotch et al.., J. Pharmaceutical Sciences 61(4):570-573 (1972), Kupchan et
al., J.
Med. Chem 17:803 (1964), Kupchan et al., Science 146:1685 (1964), Hyun et al.,
Planta Med. 61:294-295 (1995), Al-Said et al., Phytochemistry 27(10):3245-3250
(1988)). This in vitro activity was routinely shown to be non-selective, as
the
proliferation of almost all tumor cell lines was inhibited, and occurred at
similar
(generally toxic) doses across the different cell lines. Studies have also
suggested that
cardiac glycosides can be used to inhibit the export of leaderless proteins
from cells
(U.5. Patent No. 5,891,855), as well as inhibiting inflammatory cytokine
secretion
(U.5. Patent No. 5,545,623), but only at toxic doses
Based on these in vitro findings, numerous cardiac glycosides have been
screened for their ability to inhibit in vivo tumor growth. (See, for example,
LeWinn,
The Lancet June 2, 1979, p. 1196-1197; Stenkvist et al., The Lancet March 10,
1979 p.
3
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
563; Stenkvist et al., The Lancet February 25, 1982, p. 484.) However, the
results of
these in vivo studies have uniformly proven disappointing, as any therapeutic
activity
was found only at toxic doses. (Repke et al., Anti-Cancer Drug Design 10:177-
187
(1995)). Based on all of these studies, the use of cardiac glycosides as
effective anti-
neoplastic agents would be entirely unexpected.
Summary of the Invention
The present invention is based on the entirely unexpected finding that cardiac
glycosides can act as effective anti-neoplastic agents. In one aspect, the
present
1o invention provides novel methods for treating tumors that involve
administering an
effective amount of a cardiac glycoside, or a pharmaceutically acceptable
salt, ester,
amide, or prodrug thereof, to a patient in need of such treatment, wherein the
tumor is
selected from the group consisting of mesotheliomas, sarcomas, carcinomas,
stromal
cell, and germ cell tumors.
In further aspects, the present invention provides a pharmaceutical
composition
comprising an effective amount for treating tumors of a compound according to
the
general formulas hereinafter disclosed, or a pharmaceutical salt thereof, in a
suitable
carrier, and an article of manufacture comprising packaging material and the
above
pharmaceutical composition.
2o In preferred embodiments of the invention, specific compounds and
pharmaceutical compositions and articles of manufacture comprising the
specific
compounds for treating tumors.
Brief Description of the Figures
4
CA 02362917 2002-08-07
Figure 1 is a graph showing the ICSO determinations for a series of compounds
applied
to lung or colon tumors, or sarcomas.
Figure 2 is a dose response graph showing the percent inhibitory effect of
CP7079 on
a panel of tumor and normal cells.
Figure 3 is a graph comparatively showing the percent inhibitory effect of
CP7079 vs.
platinol and taxol on a panel of tumor and normal cells.
Detailed Description of the Invention
1o As used herein, the term "cardiac glycoside" ~ includes cardenolides,
bufadienolides and withanolides, with a steroid nucleus and an unsaturated
lactone ring
(which can comprise a 5 or 6 membered ring) in either the glycoside or the
free
aglycone form. (See for example, Blickenstaff, in Anti-Tumor Steroids,
Academic
Press, San Diego (1992), pp. 271-281.) Non-limiting examples of such cardiac
glycosides are disclosed in the following references
U.S. Patent Nos. 4,067,960; 3,531,462;
3,907,775; 3,907,776; 3,843,628; 3,857,832; 4,001,402; 3,939,156; 3,514,441;
3,839,317; 4,060,607; 4,003,998; 4,555,504; 3,947,404; 3,949,074; 4,133,949;
3,752,803; 3,914,213; 4,198,391; and WO 97/45216.
2o As used herein, the term "effective amount" means a dosage sufficient to
produce a desired result. The desired result can be subjective or objective
improvement
in the recipient of the dosage, a decrease in tumor size, time to progression
of disease,
...
and/or survival.
w
S
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
As used herein the term "mesothelioma" is used to refer to a neoplasm derived
from the cells lining the pleura, pericardium, or peritoneum, including but
not limited to
lung mesotheliomas.
As used herein the term "sarcoma" refers to tumors of mesenchymal origin,
including but not limited to leiomyosarcomas, malignant fibrous histiocytoma,
Ewing
sarcoma, fibrosarcomas, chondrosarcomas, osteosarcomas, liposarcomas,
rhabdomyo-
sarcomas, hemangiocytomas, and myxosarcomas.
As used herein the term "carcinoma" is used to refer to a neoplasm derived
from
epithelial cells.
1o As used herein the term "ovarian carcinoma" refers to neoplasms derived
from
ovarian cells of epithelial origin, including but not limited to ovarian
papillary serous
cystadenoma, ovarian endometroid carcinoma, mucinous, clear cell and Brenner
epithelial tumors;
As used herein the term "lung carcinoma" refers to neoplasms derived from
lung cells including but not limited to squamous cell carcinomas,
adenocarcinomas, oat
cell carcinomas, carcinoid tumors, giant cell tumors, mucoepidermoid tumors,
and
adenoidcystic carcinomas.
As used herein the term "kidney carcinoma" refers to neoplasms derived from
kidney cells including but not limited to renal cell carcinomas, Wilm's tumor,
and
2o hamartoma.
As used herein the term "germ cell tumors" refers to neoplasms including, but
not limited to, dysgerminomas, and yolk sac tumors.
As used herein the term "stromal cell tumors" refers to neoplasms including,
but not limited to granulosa cell, thecoma, and Sertoli-Leydig tumors.
6
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
In one aspect, the present invention provides new methods for treating tumors
that involve administering an effective amount of a cardiac glycoside, or a
pharmaceutically acceptable salt, ester, amide, or prodrug thereof, to a
patient in need
of such treatment, wherein the tumor is selected from the group consisting of
mesotheliomas, sarcomas, carcinomas, stromal cell, and germ cell tumors.
In a preferred embodiment, the compound comprises the general formula
O R14
R13
R11R12 ' (CHZ)n
R10_
R91 I ~--R15
R2~ I R1
R70 R6' I R4 R3
R5
1 o wherein n = 1 or 2,
a dashed line indicates an optional double bond,
R2, R4, R5, R6, R12 are selected from the group consisting of -H, -OH, OR' or
COR',
where R' is selected from the group consisting of H, or optionally substituted
alkyl,
alkoxy, alkenyl, alkenoyl, aryl, heteroaryl, or cycloaryl; or COOR", wherein
R" is
selected from the group consisting of H and optionally substituted alkyl
R3, R8, Rl l, R13 and R14 are each selected from the group consisting of -H, -
OH,
=O, OR' or COR', where R' is selected from the group consisting of H, or
optionally
2o substituted alkyl, alkoxy, alkenyl, alkenoyl, aryl, heteroaryl, or
cycloaryl; or COOR"',
wherein R"' is selected from the group consisting of H and optionally
substituted alkyl
30
or R2 and R3 together with the carbon atoms to which they are attached form an
epoxide ring;
R7 is H, or an optionally substituted alkyl, alkoxy, alkenyl, alkenoyl, aryl,
heteroaryl,
or cycloaryl;, or
a glycosidic group consisting of one or more optionally substituted sugar
residues connected by glycosidic bonds; or
7
CA 02362917 2002-08-07
O
I I
-CR(a)
where R(a) is selected from the group consisting of H, or an optionally
substituted
alkyl, alkoxy, or alkene groups,
R9 is selected from the group consisting of optionally substituted alkyl,
alkoxy,
alkenyl, alkenoyl, aryl, heteroaryl, or cycloaryl; OH, H, NH-NHZ-CONH2,
OR' or COR', where R' is selected from the group consisting of H, or
optionally
substituted alkyl, alkoxy, alkenyl, alkenoyl, aryl, heteroaryl, or cycloaryl;
or COOR"',
wherein R"' is selected from the group consisting of H and optionally
substituted
to alkyl;
O
H2N'- 'N
I
N
~CH
and
O
I I
-CH
is
R10 is selected from the group consisting of H, OH, COOH, C=ONH2, C=ONR" "H,
and
COOR"", wherein R"' represents H or an optionally substituted alkyl, alkoxy,
alkenyl, alkenoyl, aryl, heteroaryl, or cycloaryl group;
2o R15 is selected from the group consisting of H, OH, optionally substituted
alkyl,
alkoxy, alkenyl, alkenoyl, aryl, heteroaryl, or cycloaryl; and
H3C~0~.
'I0
Rl is H or OR16, where R16 is H, or an optionally substituted alkyl, alkoxy,
alkenyl,
alkenoyl, aryl, heteroaryl, or cycloaryl, or
2s
R16 and R9 together represent
-CH
I
OH =-
or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof. __
8
CA 02362917 2002-08-07
In an even more preferred embodiment, the compounds are of the general
formula
O R14
R13
R11R12
R10.
R15
R1
R~OR6~ R4 R3
s
wherein n = I or 2,
a dashed line indicates an optional double bond,
R2, R4, and R8 are selected from the group consisting of -H, -OH, and OR',
where R'
1 o consists of optionally substituted lower alkyl;
R3, Rl 3 and Rl4 are each selected from the group consisting of -H, -OH, =O,
OR",
where R" consists of optionally substituted lower alkyl;
or R2 and R3 together with the carbon atoms to which they are attached form an
epoxide ring;
15 Rl l is selected from the group consisting of -H, -OH, and =O;
R5, R6, and R12 are selected from the group consisting of H, and optionaliy
substituted alkyl, alkoxy, or alkenyl groups;
R7 is H, or an optionally substituted alkyl, alkoxy, or alkenyl groups, or
2o a glycosidic group consisting of one or more optionally substituted sugar
residues connected by glycosidic bonds; or
O
t1
-CR(a)
25 where R(a) is selected from the group consisting of H, or an optionally
substituted
alkyl, alkoxy, and alkene groups,
R9 is selected from the group consisting of optionally substituted alkyl,
alkoxy and
alkenyl groups; OH, H, NH-NHZ-CONHZ,
9
CA 02362917 2002-08-07
O
H2N~N
I
N
~CH
and
O
I I
-CH
Rl 0 is selected from the group consisting of H, OH, COOH, C=ONH2, C=ONR" "H,~
and
COOR"', wherein R"' represents H or an optionally substituted alkyl group;
R15 is selected from the group consisting of H, OH, an optionally substituted
alkyl,
alkoxy, and alkenyl groups; and
H3C~0
O
Rl is H or OR16, where R16 is H, or
1o R16 and R9 together represent
-CH
I
OH
or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
Unless indicated otherwise, the alkyl, alkoxy, alkenyl, alkenoyl, aryl,
heteroaryl,
cycloaryl, and glycosidic group substituents herein can be optionally
substituted with at
~ 5 least one group independently selected from hydroxyl, carboxyl, amine,
halogen, or
phenyl groups. Additionally, the glycosidic groups can be optionally
substituted with
at least one group independently selected from alkyl, alkoxy, and alkenyl
groups.
By "alkyl", "lower alkyl", and "(C,-C,o)-alkyl" in the present invention is
meant straight or branched chain alkyl groups having 1-10 carbon atoms, such
as
20 preferably C~-C6, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,
tent-butyl, : ,
pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, decyl, octyl,
and 3-
methylpentyl. These groups may be substituted, for instance with halo, alkyl,
amino,
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
alkylamino, dialkylamino, hydroxy, alkoxy and the like. Examples include
chloromethyl, 2-amino ethyl, and 3-dimethyl-aminopropyl.
By "alkenyl", "lower alkenyl" and (CZ-Clo)alkenyl is meant straight or
branched
chain alkyl groups having 1-10 carbon atoms and having one or two nonadjacent
double bonds. Examples of alkenyls include, but are not limited to, 3-butenyl
and 1-
methyl-3-pentenyl.
By "alkynyl", "lower alkynyl" and (CZ-C~o)alkynyl is meant straight or
branched chain alkyl groups having 1-10 carbon atoms and having a triple bond.
Typical alkynyl groups include 2-propynyl and 1,1-dimethyl-3-butynyl.
Substituted
to alkenyl and alkynyl groups include 4,4-dibromo-2-pentenyl and 3-amino-5-
hexynyl.
By "alkoxy", "lower alkoxy" or "(C~-Coo)-alkoxy" in the present invention is
meant straight or branched chain alkoxy groups having 1-10 carbon atoms, such
as, for
example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-
butoxy,
pentoxy, 2-pentyl, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and 3-
methylpentoxy.
The term "alkanoyl" means an alkyl group bonded through a carbonyl moiety.
Examples include acetyl and pentanoyl. "Aminoalkanoyl" means the alkyl group
is
substituted with an amino group. Examples include aminoacetyl and 3-
aminohexanoyl.
"Alkylaminoalkanoyl" means an aminoalkanoyl group wherein the amine is
substituted
2o with a C~-Clo alkyl group, and includes methylaminoacetyl and 4-
(isobutylamino)-
octanoyl. "Dialkylaminoalkanyl" means an N,N-di-substituted aminoalkanoyl
group
such as diisopropylaminoacetyl.
By halogen in the present invention is meant fluorine, bromine, chlorine, and
iodine.
11
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
The term "aryl" means an unsubstituted aromatic carbocyclic group having a
single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple
condensed rings in
which at least one is aromatic (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl,
anthryl, or
phenanthryl). The term "substituted aryl" means, unless stated otherwise, an
aryl
substituted by 1 to 4 substituents selected from alkyl, O-alkyl and S-alkyl, -
OH, -SH, -
CN, halogen, 1,3-dioxolanyl, -CF3, -NO2, -NHZ, -NHCH3, -N(CH3)2, -NHCO-alkyl,
-(CH2)n,CO2H, -(CHZ)n,C02-alkyl, -(CHZ)n,S03H, -NH alkyl, -N(alkyl)Z, -
CHZ)n,P03H2,
-(CH2)mP03(alkyl)Z, -(CHZ)mSOzNH2, and -(CHZ)mSO2NH-alkyl wherein alkyl is
defined as above and m is 0, l, 2, or 3.
1o By "heteroaryl" is meant one or more aromatic ring systems of 5-, 6-, or 7-
members containing at least one and up to four heteroatoms selected from
nitrogen,
oxygen, or sulfur. Such heteroaryl groups include, for example, thienyl,
furanyl,
thiazolyl, imidazolyl, (is)oxazolyl, tetrazolyl, pyridyl, pyridonyl,
pyrimidinyl, pyrazole,
(iso)quinolinyl, napthyridinyl, phthalimidyl, benzimidazolyl, benzoxazolyl. A
"substituted heteroaryl" group can be substituted with one, two, three, or
four of the
groups mentioned above for "substituted aryl", such as 2,3,4,6-
tetrachloropyridyl and
2-methoxy-3-trifluoromethylthien-4-yl.
A "carbocyclic group" or "cycloalkyl" is a nonaromatic cyclic ring or fused
rings having from 3 to 7 ring carbon members. Examples include cyclopropyl,
2o cyclobutyl, and cycloheptyl. These rings may be substituted with one or
more of the
substituent groups mentioned above for aryl, for example alkyl, halo, amino,
hydroxy,
and alkoxy. Typical substituted carbocyclic groups include 2-
chlorocyclopropyl, 2,3-
diethoxycyclopentyl, and 2,2,4,4-tetrafluorocyclohexyl. The carbocyclic group
may
contain one or two heteroatoms selected from oxygen, sulfur, and nitrogen, and
such
12
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
ring systems are referred to as "heterocyclyl" or "heterocyclic". Examples
include
pyranyl, tetrahydrofuranyl, and dioxanyl. These heterocyclyl groups may be
substituted
with up to four of the substituent groups mentioned for aryl to give groups
such as 3-
chloro-2-dioxanyl, and 3,5-dihydroxymorpholino.
By "glycosidic group" in the present invention is meant one or more optionally
substituted sugar residues connected by glycosidic bonds.
The term "pharmaceutically acceptable salts, esters, amides, and prodrugs" as
used herein refers to those carboxylate salts, amino acid addition salts,
esters, amides,
and prodrugs of the compounds of the present invention which are, within the
scope of
1o sound medical judgment, suitable for use in contact with the tissues of
patients without
undue toxicity, irritation, allergic response, and the like, commensurate with
a
reasonable benefit/risk ratio, and effective for their intended use, as well
as the
zwitterionic forms, where possible, of the compounds of the invention. The
term "salts"
refers to the relatively non-toxic, inorganic and organic acid addition salts
of
compounds of the present invention. These salts can be prepared in situ during
the final
isolation and purification of the compounds or by separately reacting the
purified
compound in its free base form with a suitable organic or inorganic acid and
isolating
the salt thus formed. Representative salts include the hydrobromide,
hydrochloride,
sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate,
stearate, laurate,
2o borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate,
succinate,
tartrate, naphthylate mesylate, glucoheptonate, lactobionate, and
laurylsulphonate salts,
and the like. These may include cations based on the alkali and alkaline earth
metals,
such as sodium, lithium, potassium, calcium, magnesium, and the like, as well
as non-
toxic ammonium, quaternary ammonium, and amine cations including, but not
limited
13
CA 02362917 2002-08-07
to ammonium, tetramethylammonium, tetraethylammonium, methylamine,
dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See,
for
example, Berge S.M. et al., "Pharmaceutical Salts," J. Pharrn. Sci., 1977;66:1-
19).
Examples of pharmaceutically acceptable, non-toxic esters of the compounds of
this invention include C~-C~~ alkyl esters, wherein the alkyl group is a
straight or
branched, substituted or unsubstituted, CS-C~ cycloalkyl esters, as well as
arylalkyl
esters such as benzyl and triphenylmethyl. C~-C4 alkyl esters are preferred,
such as
methyl, ethyl, 2,2,2-trichloroethyl, and tort-butyl. Esters of the compounds
of the
present invention may be prepared according to conventional methods.
Examples of pharmaceutically acceptable, non-toxic amides of the compounds
of this invention include amides derived from ammonia, primary C~-C6 alkyl
amines
and secondary C~-CG dialkyl amines, wherein the alkyl groups are straight or
branched.
In the case of secondary amines, the amine may also be in the form of a 5- or
6-
membered heterocycle containing one nitrogen atom. Amides derived from
ammonia,
C~-C3 alkyl primary amines and C~-C2 dialkyl secondary amines are preferred.
Amides
of the compounds of the invention may be prepared according to conventional
methods.
The term "prodrug" refers to compounds that are rapidly transformed in vivo to
yield the parent compound of the above formulae, for example, by hydrolysis in
blood.
A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella,
"Pro-drugs
as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in
Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American
Pharmaceutical Association and Pergamon Press, 1987.
14
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
Most preferred compounds to carry out the method of the invention include
digitoxin (CP4071 ), CP 7079, ouabain (CP4255), convallatoxin (CP2575M),
oleandrin
(CP6963M), oleandrigenin (CP6963MG), bufalin (CP1493M), periplocymarin
(CP7918), digoxin (CP4072), strophanthidin oxime (CP7998), strophanthidin
acetate
(CP7992), strophanthidin semicarbazone (CP7995), strophanthidinic acid lactone
acetate (CP7999), strophanthidin (CP7997), emicymarin (CP7590), digoxigenin
(CP7501), sarmentoside D (CP7978), sarverogenin (CP7985), sarmentoside A
(CP7980), gitoxigenin diacetate (CP7655), ouabagenin (CP7030M), sarmentogenin
(CP7973), CP6997, and gitoxigenin (CP7656)
1o In another aspect, preferred compounds of the instant method comprise the
general formula
R1
R5
HO
wherein Rl, R2, R3, R4 and RS are selected from the group consisting of H, =O,
OH,
optionally substituted alkyl, alkoxy, and alkene groups; -N-OH, NH-NH2-CONHZ,
HNC=O, RBNC=O, and COORB, wherein R8 represents H or an optionally substituted
alkyl, alkoxy, or alkenyl group; OR6 or COR6, where R6 is selected from the
group
consisting of H, or optionally substituted alkyl, alkoxy, alkenyl, amino,
dialkylamino,
aryl, or heteroaryl; or COOR7, wherein R7 is selected from the group
consisting of H
and optionally substituted alkyl, alkoxy, and alkenyl groups.
2o In an even more preferred embodiment, the compounds are of the general
formula
CA 02362917 2002-08-07
f'1 A
HO
R3
wherein Rl, R2, R3, R4 and RS are selected from the group consisting of H, =O,
OH, -
N-OH, NH-NH2-CONH2, and optionally substituted alkyl, alkoxy, and alkene
groups;
or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
5 A most preferred embodiment consists of cassaine sulfate (CP7404).
In further aspects, the present invention provides a pharmaceutical
composition
comprising an effective amount for treating specified tumors of a compound
according
to one of the above general formulas, or a pharmaceutical salt thereof, in a
suitable
carrier, and an article of manufacture comprising packaging material and the
above
pharmaceutical composition.
In preferred embodiments of the invention, specific compounds and
pharmaceutical compositions and articles of manufacture comprising the
specific
compounds for treating tumors.
The compounds disclosed herein can be prepared by any of the methods known
I S in the literature. Non-limiting examples of these methods include those
disclosed in
U.S. Patent Nos. 3,514,441; 3,531, 462; 3,843, 628; 3,857,832; 3,939,156;
3,949,074;
and 4,001,402.
Alternatively, a number of the compounds are commercially available (for
example,
Sigma Chemical Co., St. Louis, MO).
2o The present compounds are useful in treating mesotheliomas, sarcomas,
carcinomas, stromal cell and germ cell tumors. Examples of specific tumor
types that
16
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
the compounds may be used to treat include, but are not limited to solid
tumors,
including ovarian papillary serous cystadenoma and ovarian endometroid
carcinoma,
lung mesothelioma, malignant fibrous histiocytoma, leiomyosarcoma, Ewing
sarcoma,
hemangiocytomas. Other ovarian tumors, such as mucinous, clear cell and
Brenner
epithelial tumors; germ cell tumors including dysgerminomas and yolk sac
tumors; and
stromal cell tumors including granulosa cell, thecoma, and Sertoli-Leydig
tumors, are
also treatable. Other sarcomas treatable with the compounds of the invention
include
fibrosarcomas, chondrosarcomas, osteosarcomas, liposarcomas,
rhabdomyosarcomas,
and myxosarcomas.
to Preferred examples of carcinomas that may be treated with the compounds of
the invention include ovarian, kidney, and lung carcinomas.
In another preferred embodiment, the compounds are used to treat ovarian
papillary serous cystadenomas, ovarian endometroid carcinomas, mesotheliomas,
malignant fibrous histiocytomas (a sarcoma), leiomyosarcomas, hemangiocytomas,
liposarcomas, and Ewing sarcomas.
The instant compounds can be administered individually or in combination,
usually in the form of a pharmaceutical composition. Such compositions are
prepared
in a manner well known in the pharmaceutical art and comprise at least one
active
compound. Accordingly, the present invention also includes pharmaceutical
2o compositions comprising as active ingredient certain compounds of the
disclosed
compounds associated with a pharmaceutically acceptable carrier. The invention
further
comprises the method of treating susceptible neoplasms using the compositions
containing as an active ingredient one or more of the disclosed compounds.
17
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
The compounds of the invention can be administered as the sole active
pharmaceutical agent, or they can be used in combination with one or more
other anti-
tumor agents. When administered as a combination, the therapeutic agents can
be
formulated as separate compositions that are given at the same time or
different times,
or the therapeutic agents can be given as a single composition.
The compounds may be made up in a solid form (including granules, powders
or suppositories) or in a liquid form (e.g., solutions, suspensions, or
emulsions). The
compounds of the invention may be applied in a variety of solutions and may be
subjected to conventional pharmaceutical operations such as sterilization
and/or may
1o contain conventional adjuvants, such as preservatives, stabilizers, wetting
agents,
emulsifiers, buffers etc.
For administration, the compounds are ordinarily combined with one or more
adjuvants appropriate for the indicated route of administration. The compounds
may be
admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic
acids, stearic
acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of
phosphoric and sulphuric acids, acacia, gelatin, sodium alginate,
polyvinylpyrrolidine,
and/or polyvinyl alcohol, and tableted or encapsulated for conventional
administration.
Alternatively, the compounds of this invention may be dissolved in saline,
water,
polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal
solutions,
2o ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum,
and/or various
buffers. Other adjuvants and modes of administration are well known in the
pharmaceutical art. The carrier or diluent may include time delay material,
such as
glyceryl monostearate or glyceryl distearate alone or with a wax, or other
materials well
known in the art.
18
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
Pharmaceutical compositions containing the compounds described herein are
administered to an individual having a tumor. In therapeutic applications,
compositions
are administered to a human patient in an amount sufficient to cause
regression of the
tumor, or at least partially arrest tumorigenesis and metastasis. Amounts
effective for
this use depend on factors including, but not limited to, the nature of the
compound
(specific activity, etc.), the manner of administration, the stage and
severity of the
cancer, the weight and general state of health of the patient, and the
judgment of the
prescribing physician. The active compounds are effective over a wide dosage
range.
For example, dosages per day will normally fall within the range of about 1
pg/kg to
1 o about 0.8 mg/kg of body weight. In the treatment of adult humans, the
range of about 1
~,g/kg to about 0.1 mg/kg of body weight, in single or divided doses, is
preferred, while
5 pg/kg to about 30 pg/kg is most preferred. However, it will be understood
that the
amount of the compound actually administered will be determined by a
physician, in
the light of the relevant circumstances including the condition to be treated,
the choice
of compound to be administered, the chosen route of administration, the age,
weight,
and response of the individual patient, disorders affecting the heart, and
other specific
organ dysfunction. Therefore, the above dosage ranges are not intended to
limit the
scope of the invention in any way.
The compounds of the invention may be administered by any suitable route,
2o including orally, parentally, by inhalation or rectally in dosage unit
formulations
containing conventional pharmaceutically acceptable carriers, adjuvants, and
vehicles,
including liposomes. The term parenteral as used herein includes,
subcutaneous,
intravenous, intraarterial, intramuscular, intrasternal, intratendinous,
intraspinal,
intracranial, intrathoracic, infusion techniques, intracavity, or
intraperitoneally. In a
19
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
preferred embodiment, the compounds of the invention are administered orally
or
parentally.
The instant invention may be embodied in other forms or carried out in other
ways without departing from the spirit or essential characteristics thereof.
The present
disclosure and enumerated examples are therefore to be considered as in all
respects
illustrative and not restrictive, the scope of the invention being indicated
by the
appended claims, and all equivalency are intended to be embraced therein. One
of
ordinary skill in the art would be able to recognize equivalent embodiments of
the
instant invention, and be able to practice such embodiments using the teaching
of the
instant disclosure and only routine experimentation.
Examples
1. Tissue Processing
Excess tissue specimens obtained from a variety of organs and tissues such as
colon, lung, kidney, stomach, and buttocks were obtained freshly at the time
of surgery
and samples were sent for pathological testing. For diagnosis and grading of
tissue
samples (ie: prior to processing), hematoxylin and eosin stained tissue
sections were
examined by a pathologist. If the diagnosis and grading of the tissue
concurred with
2o the determination made by the surgical pathologist that provided the
tissue, then the
tissue was used in the screen. If there was no agreement, then two additional
pathologists served as referees. If no consensus was reached, then the tissue
was
discarded.
The remaining tissue was used to prepare cell suspensions. The tissue was
initially treated enzymatically via standard methods until only undigested
material
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
remained. The resulting cell suspension was further purified via isokinetic
density
centrifugation.
Additional normal cells were removed from the cell suspension by negative
immunoselection with a combination of monoclonal antibodies linked to magnetic
beads (Dynal) that were used according to the manufacturers' instructions. The
remaining cells were placed into appropriate medium, frozen down in one ml
aliquots,
and stored until use.
Example 2. General ScreenlBioassay Procedures
to After tissue processing, the relative purity of the resulting cell
suspension was
determined by cytological examination after pap staining. Only those cell
preparations
greater than 80% tumor cells were used for testing of candidate compounds. If
there
was any doubt about the percentage of tumor cells in the cell preparation,
additional
pathologists served as referees to make a determination.
Cell preparations that passed histological and cytological examination for
diagnosis, grading, and cell purity were thawed at 37°C and resuspended
in tissue
culture medium designed to maintain the cells during the incubation period.
The live
and dead cells were counted and the cells were diluted in culture medium to
4.0 x 104
live cells/ml for tumor cells and 1.32 x 105 live cells/ml for normal cells.
2o The cells were added to microtiter plates and incubated at 37°C for
one hour
with 10 ~m of the candidate compounds that were added at 1/lOth the volume of
the
cell suspension. Alamer Blue (Accumed International, Westlake OH) was then
added
to the cells at 1/10 the volume of the well, and the cells were further
incubated at 37°C
for various times. Alamer Blue dye measures cellular re-dox reactions (ie:
cellular
21
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
respiration) whereby a spectral shift occurs upon reduction of the dye.
(Excitation 530
nm; emission 590 nm)
The kinetics of cellular re-dox reactions were subsequently measured at
various
times, for example at 3 hours, 3 days, and S days post-dye addition. These
measurements, in comparison with control cells (untreated with compound) and
media
controls (test wells without cells) provide the percent inhibition of cellular
respiration
as a result of candidate compound treatment, as well as ICso determinations.
The Alamer Blue data were subsequently confirmed by microscopic
observation, and by the use of calcein AM (Molecular Probes, Eugene OR), a
cell
l0 permeant esterase substrate that measures both esterase activity and cell
membrane
activity. If the cell is alive, the dye is converted into a fluorogenic
substrate by
intracellular esterases and is retained by the cell (excitation 485 nm;
emission 530 nm).
If the cells are dead, the calcein AM rapidly leaks from the cells and is not
converted
into a fluorogenic substrate. Thus, the assay is useful for cytotoxicity
testing.
Example 3. Anti-Tumor Pilot Screen
In a blinded fashion, approximately 10,000 compounds were tested at a rate of
1,000-4,000 compounds per run set against colon, lung, and sarcoma tumors. The
anti-
tumor screen utilized was composed of three tiers as follows. In screen 1,
patient
2o tumor cells were tested in singles, with candidate compounds at a
concentration of 10
pM. Samples that showed at least 80% inhibition (compared to cell and media
controls) and/or two standard deviations from the mean of the plate samples
were
advanced. In the first part of the second test (screen 2a), the compounds were
re-
tested, in duplicate, at 10 pM concentrations on patient tumors. Compounds
that re-
22
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
confirmed were then tested, in duplicate, at 10 pM concentration on patient
normal
cells. Samples that exhibited at least 80% inhibition on tumor cells and no
more than
20% inhibition of normal cells were tested in the second part (screen 2b). At
this level,
the ICSO of the remaining candidate compounds were assayed, in triplicate, on
both
patient tumor (screen 3a) and patient normal cells (screen 3b).
A summary of the results from this pilot screen is shown below:
ANTI-TUMOR PILOT SCREEN RESULTS
Tumor Sarcoma Lung Colon
# compounds tested 8,000 9,920 9,840
Screen 1: # compounds with
requisite result 326 232 326
Screen 2aT: # reconfirmed 209 182 227
Screen 2aN: # with requisite
normal cell result 40 30 34
Screen 2b: # compounds with
ICSO no more than 500 nM 6 8 6
To briefly summarize the results of the first phase of the screen, the "hit
rate" in
screen 1 ranged between 2.3% and 4.1%. Furthermore, throughout the run set,
the
coefficient of variation for the plate controls was approximately 10% (data
not shown).
The reconfirmation rate for the three tumors ranged between 64% and 78%. The
percentage of active compounds that did not exhibit gross toxicity on normal
cells was
between 0.3% and 0.5% of the compounds tested in screen 1. Lastly, the
percentage of
compounds that have ICSO no more than 500 nM was approximately 0.08% of the
compounds tested in screen 1.
3o Included in the pilot screen in a "blinded fashion" were 480 generic drugs
including 13 anti-neoplastic compounds. None of the anti-neoplastic compounds
23
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
passed the screen. Two compounds (cyclophospamide and methotrexate) would not
have been anticipated to demonstrate in vitro activity. The remaining
compounds
either did not demonstrate at least 80% inhibition of tumor cells at 10 ~M or
showed
greater than 20% inhibition of normal cells.
In an effort to discover additional compounds that are both potent and
selective,
upon completion of the first round of the screen, partial ICSO were performed
for both
screens 2aT and 2aN. This allowed for the detection of compounds that may have
failed the first round of testing because, the screen did not allow discovery
of potent
anti-tumor compounds that exhibited more than 20% inhibition of normal cells
at 10
Vim. Therefore, the 362 compounds originally selected from screen 1 were
tested in
screen 2aT in duplicate at 1.0 pM, 100 nM, and 10 nM. Twenty compounds, five
compounds, and four compounds, respectively, demonstrated at least 80%
inhibition of
tumor cells at these concentrations.
These 29 compounds were then tested in screen 2aN, in duplicate. Starting at
6.3 ~M, five serial five-fold dilutions were tested. Based on these results,
seven
compounds were advanced to screen 2b where they were tested against tumor and
normal cells, in triplicate, in eight half log dilutions. A summary of the
combined
results for 13 of the compounds are shown in Figure 1. Three of the compounds
identified in screen 2b are structural analogs of each other.
The three compounds, CP4255, CP7079, and CP7978, that were structurally
similar demonstrated anti-tumor activity and good potency (Figure 1). A
composite
dose-response curve of an example of the class of compounds is shown in Figure
2 for
candidate compound CP7079. Upon testing a wider range of tumor types, the
class of
compound was demonstrated to be most active on sarcomas, ovarian carcinomas,
and
24
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
mesothelioma-type tumors. In comparison, the compounds were less active on
colon
and lung tumors, as well as melanomas and other tumors derived from stomach,
kidney,
and gall bladder (data not shown). Figure 3 compares these CP7079 with
platinol and
taxol on an ovarian carcinoma, sarcoma, and normal lung cells. Taken together,
the
data show that these compounds exhibit both anti-tumor activity and good
potency.
Example 4. Identification of additional anti-tumor compounds
CP4255, CP7079, and CP7978 were subsequently identified as cardiac
glycosides. In an effort to identify further compounds structurally related to
these three
1o compounds that exhibited similar or improved anti-tumor efficacy, a series
of
structurally related cardiac glycosides were tested as in Example 3.
The following compounds showed the desired efficacy:
o p O
~o
0
Me O
Me HO Me Me H O
O ,, O
Ho., O O~ 0 ,
H off O
HO~~ ' O , OHO ' O O O
H Me H H O
Di itoxin CP4071 CP7079
0 0
0
CH
CH
O~~CH H
CH H ! 1
H OH
H OH O p ~ OH
HO H CH
OH OH
Bufalin CP 1493M Convallatoxin CP2575
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
O O
O
'O
HO
HO Me
OH H~o OH
H
HO., OH
H OH HO O H
OH
O~O
Me H OH
Ouabain CP4255 Peri loc arin CP7918
0 0 0
~o
OH
HO Me I
N
Me HO Me
Me H
0,
HO., O O H OH OH
H HO
Me OH
Di oxin (CP4072 Stro hanthidin oxime CP7998
0 0 0
0 0
HzN NH
I
N
O
OH
OH HO
OH
O O OH
Stro hanthidin acetate CP7992 Stro hanthidin semicarbazone CP7995
0 0
O O
0
C7 H
HO
O OH
O
HO
Strophanthidinic acid lactone, acetate Strophanthidin (CP7997)
CP7999
26
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
O O
O O
OH
t7 H
OH HO
HO
O
~O
OH
O
OH
Emic marin CP7590 Di oxi enin CP7501
0 o
0
0
HO
O
O~ '
OH
O O p HO
p O ' H
~
O
O
O
Sarmentoside D (CP7978) Sarvero enin (CP7985)
O O
O O
HO O
O //
,H O
I
H O
HO ~ H
O
O ~( OH O
OH
Sarmentoside A (CP7980 Gitoxi enin diacetate (CP7655
0 0 0
HO
CH3
CH H O~CH3
II H
v
~
O HO
H OH
HO H
H
Oleandrogenin (CP6963MG) Sarmentogenin (CP7973)
27
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
O O
O
'O
OH
OH
HO
O ~ H
OH
O OH
CP6997 Gitoxi enin CP7656
o ° , °~Ni
n
CH3
CH H O CH3
HO O
H OH O
HsC O O H
HO
OMe
Oleandrin CP6963M Cassaine sulfate CP7404
O
CH3
HO.
HO
HO H
1
H OH
HO
OH
Ouabagenin (CP7030)
Compound CP7079 is one of alpha-antiarin, beta-antiarin, or antialloside,
which
differ from each other only in the stereochemistry of the sugar residue. Only
the
structure for alpha-antiarin is found in The Merck Index (p. 117; Merck & Co.,
Inc.
Publishers, 12'h edition, 1996). In any event, all three of the compounds
should be
effective in the assay.
A summary of the results of studies carned out on cells isolated from a
sarcoma
taken from a single patient is presented in Table 1.
28
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
TABLE 1
COMPOUND IC50 (nM) TUMOR TYPE
Convallatoxin CP2575M 3.8 Sarcoma
Ouabain CP4255 4.6 Sarcoma
Oleandrin CP6963M 4.8 Sarcoma
CP7079 10 Sarcoma
Oleandro enin CP6963MG 12.1 Sarcoma
Di itoxin CP4071 13 Sarcoma
Bufalin CP1493M 13 Sarcoma
Di oxin CP4072 14 Sarcoma
Peri loc marin CP7918 28 Sarcoma
Stro hanthidin semicarbazone 38 Sarcoma
CP7995
Stro hanthidin oxime CP7998 40 Sarcoma
Stro hanthidin acetate CP7992 42 Sarcoma
Cassaine sulfate CP7074 67 Sarcoma
Stro hanthidin CP7997 93 Sarcoma
Stro hanthidic acid lactone 93 Sarcoma
acetate CP7999
Sarmentoside D CP7978 137 Sarcoma
Emic marin CP7590 139 Sarcoma
Sarvero enin CP7985 162 Sarcoma
Di oxi enin CP7501 215 Sarcoma
Gitoxi enin diacetate CP7655 728 Sarcoma
Ouaba enin CP7030M 970 Sarcoma
Sarmento enin CP7973 1100 Sarcoma
CP6997 2510 Sarcoma
Gitoxi enin CP7656 3000 Sarcoma
Similar experiments were performed on cells isolated from ovarian tissue taken
from two separate patients. The following results were obtained:
TABLE 2
Com ound IC50 on cells from IC50 on cells from
atient 1 anent 2
Di itoxin CP4071 --- 31 nM
Di oxin CP4072 3.7 nM 56 nM
CP7079 4.3 nM 13 nM
Oubain CP4255 5.5 nM 16 nM
Sarmentoside D CP797877 nM 280 nM
Sarmentoside A CP7980------ 470 nM
The differences in ICSO values of the compounds observed between the two
ovarian tumor patients may represent patient heterogeneity or could indicate a
difference in the specific ovarian tumor type.
29
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
Taken together, these data show that the cardiac glycosides of the invention
can
be used as anti-neoplastic agents at relatively non-toxic concentrations.
Based on all of the above data, the present invention surprisingly provides
needed methods and pharmaceutical compositions for treating mesotheliomas,
sarcomas, carcinomas, stromal cell, and germ cell tumors.
Example 5. Phase II Evaluation of CP4071 in previously treated advanced
sarcomas.
A. Statement of Stud ,Y Purpose: Rationale
1. To evaluate the efficacy, as measured by the response rate, of digitoxin
given daily
to patients with unresectable or metastatic sarcoma who have failed one or
more prior
treatment regimens.
2. To assess the clinical and laboratory toxicities of this dose/schedule of
oral CP4071.
1. BACKGROUND
Soft tissue sarcomas represent 0.7% of all malignancies diagnosed in the
United
States, but the morbidity is great in that the peak incidence of these tumors
is seen in
children and young adults (1,2). A second peak occurs in late middle-age,
resulting in
significant morbidity in productive adults (2). Although the primary treatment
of these
tumors has improved, with limb-preserving surgery and radiation therapy
resulting in
improved functional ability, the treatment of metastatic disease is
unsatisfactory and
systemic chemotherapy as a post-surgical adjuvant is of unproven value (2).
Only three
agents - doxorubicin, ifosfamide and dacarbazine - are accepted as having
useful
3o activity in this group of diseases and combination chemotherapy regimens
have not
been demonstrated to result in a survival duration superior to that produced
by therapy
with single agents (2-6). Clearly, new agents with activity in soft tissue
sarcomas need
to be identified if therapy of these tumors is to improve.
Of the cardiac glycosides tested, digitoxin was determined to be the best drug
for clinical trials in patients who have sarcomas. Digitoxin appeared more
active in the
assays then digoxin. Digitoxin and oubain were equally active but the oubain
would
need to be given by an intravenous infusion, as opposed to the convenience of
orally
available digitoxin.
0 1.1 Pharmacolo~y- Digitoxin is extracted and crystallized from Digitalis
purpurea. It
has been used to treat cardiovascular disease for decades.
The activity of digitoxin on the myocardium is dose-related, and involves both
a
direct action on myocardium, the specialized conduction system and indirect
actions on
the cardiovascular system mediated by the autonomic nervous system. These
indirect
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
actions involve a vagomimetic action (depression of atrioventricular node and
a
baroreceptor sensitization) that results in increased carotid sinus nerve
activity and
enhanced sympathetic withdrawal for any given increment in mean arterial
pressure.
Digitalis has a direct inotropic effect on the myocardium At higher doses
digitalis increases sympathetic outflow from the CNS to both cardiac and
peripheral
sympathetic nerves. The result may be increased atrial or ventricular rates,
possibly an
important factor in digitalis cardiac toxicity.
The cellular basis for the inotropic effects of the digitalis glycosides
appears to
be inhibition of sodium and potassium ATPase in the sarcolemma, which alters
1o excitation-contraction coupling. By inhibiting sodium and potassium-ATPase
the
digitalis glycosides make more calcium available to activate the contractile
proteins,
actin and myosin.
The mechanism of the antitumor activity of cardiac glycosides is not known.
1.2 Pharmacokinetics:
Digitoxin is greater than 90% absorbed following oral administration. When
taken with food, absorption is slowed but complete, except when taken with
meals
high in bran fiber.
Cardiac glycosides are widely distributed in tissues. High concentrations are
found in the myocardium, skeletal muscle, liver, brain and kidneys.
Fifty-80% of administered digitoxin is degraded by the liver to inactive
metabolites that are excreted by the kidneys. About 8% is converted to
digoxin.
Digitoxin has a serum half life of 7-9 days. As a result, clinical effects do
not
fully develop until steady state levels (approximately 5 half lives) are
achieved, and 3-5
weeks are needed for complete dissipation of digitoxin effects following
discontinuation. Digitoxin is greater than 95% bound to plasma proteins. The
bound
drug is in equilibrium with the unbound fraction. At equilibrium, the
concentrations in
cardiac tissue are 15 to 30 times those in the plasma; the concentration in
skeletal
3o muscle is about half that in the heart. Digitoxin is not effectively
removed by
peritoneal or hemodialysis, probably due to its high degree of plasma protein
binding.
2. STUDY RATIONALE. Both in vitro and epidemiological data suggest that the
cardiac glycosides have antitumor activity. Since the risks of digitoxin
administration
are well known in humans, it is appropriate to determine if doses routinely
used to treat
patients with cardiac disorders are sufficient to achieve an antitumor effect
in patients
with various sarcomas.
3. STUDY DRUG
45
3.1 CP4071 (digitoxin) is a single cardiac glycoside extracted from the leaves
of
Digitalis purpurea. Digitoxin is: card-20 (22)-enolide,3-[(O-2,6-dideoxy-(3- D
-ribo-
hexopyranosy- (1-4) -2,6- dideoxy-(3- D - ribo-hexopyranosy) oxy]-14 hydroxy,
(3(3,5(3). Digitalis has been used to treat cardiovascular disease for many
decades.
3.2 Source of Drug: Digitoxin (Medisca) will be provided by the pharmacist as
a
liquid. It is formulated to contain 0.05 mg digitoxin/ml, 20% ethanol (USP),
10%
propylene glycol, 200 mg aspartame and creme de mint qs ad 8 oz water. The
31
CA 02362917 2001-08-13
w0 00/47215 PCT/US00/03564
digitoxin will be provided in capped syringes each containing a single
premeasured
dose of drug which can be either taken directly or first diluted in a small
amount of
liquid.
3.3 Drug Dosage: Eligible patients initially will be slowly digitalized, with
4 ml (0.2
mg) digitoxin twice daily for 4 days, followed by a maintenance dosage of 1 ml
(0.05)
to 6 ml (0.3 mg). The initial maintenance dose will be O.lSmg daily. If after
six weeks
at 3m1 (0.15 mg) daily there is no evidence of digitalis toxicity (ECG,
digitoxin blood
level, GI or visual symptoms, the maintenance dose may be increased to 4 ml
(0.2 mg)
to daily. If after six weeks at 4 ml (0.2 mg) daily there is no evidence of
digitalis toxicity
(ECG, digitoxin blood level, GI or visual symptoms), the maintenance dose may
be
increased to 5 ml (0.25 mg) daily. All patients must start at the 3 ml (0.15
mg)
digitoxin dose and may be escalated to the 5 ml (0.25 mg) dose if tolerated in
the above
schedule.
20
If a patient experiences a Grade 3 or Grade 4 arrythmia, the digitoxin dose
will be withheld. Once resolved, the patient may be restarted at the next
lower non cardiotoxic dose.
3.5 PRECAUTIONS
3.5.1. Electrolyte imbalance:
Potassium - Hypokalemia sensitizes the myocardium to digitalis. Toxicity may
develop even with serum glycoside levels in the "normal" range. Therefore, it
is
important to maintain normal serum potassium levels. Potassium wastage may
results
from diuretic or corticosteroid therapy, hemodialysis or from suction of
gastrointestinal
secretions. It may also accompany malnutrition, diarrhea, prolonged vomiting,
old age
3o or long-standing congestive heart failure. Infusion of carbohydrate
solution may lower
serum potassium by causing an intracellular shift of potassium. In general
avoid rapid
shifts in serum potassium or other electrolytes.
Calcium - Hypercalcemia from any cause predisposes the patient to digitalis
toxicity.
The effect of cardiac glycosides on the myocardium are reduced by
hypocalcemia.
Magnesium - Hypomagnesemia may predispose to digitalis toxicity. If low
magnesium levels are detected, magnesium levels will be restored with oral or
intravenuous supplementation as required.
3.5.2. Cardiac Problems:
Patients with incomplete AV block, especially subject to Stokes-Adams syndrome
may
develop advanced or complete heart block. Patients with acute myocardial
infarction,
severe pulmonary disease, severe carditis (e.g. carditis associated with
rheumatic fever
or viral myocarditis) or advanced heart failure may be more sensitive to
digitalis and
prone to rhythm disturbances.
32
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
Drug Interactions:
A variety of drugs may affect the serum concentration of cardiac glycosides
via various
mechanisms (e.g., altered GI flora, decreased clearance.) possibly increasing
the
therapeutic or toxic effects.
Beta Mockers: These drugs may inhibit AV nodal conduction and can result in
complete heart block.
Nondepolarizing muscle relaxants and succinylcholine: When administered with
1o digitalis glycosides, cardiac arryhthmias may be increased.
Potassium-sparing diuretics: Spironolactone may increase or decrease toxic
effects of
digitalis glycosides. Changes cannot be predicted and patients should be
carefully
monitored. Amiloride may decrease inotropic effects of digoxin; triamterene
may
15 increase its pharmacological effects.
Sympathomimetics: Concomitant use with digitoxin can increase the risk of
cardiac
arrhythmias because both enhance ectopic pacemaker activity.
2o Thiazide and loop diuretics and amphotheracin B increase potassium loss,
possibly
resulting in hypokalemia and will be used with caution in patients receiving
CP4071.
Thyroid hormones: Thyroid hormones may decrease the therapeutic effectiveness
of
cardiac glycosides, and thioamines may increase their therapeutic and toxic
effects.
3.5.3 Contraindications:
A previous toxic response to digitalis preparations, ventricular fibrillation,
ventricular
tachycardia, beriberi heart disease, allergy to digitalis, although rare may
occur and
some cases of hypersensitive carotid sinus syndrome.
Pregnancy: Category C. Digitoxin rapidly crosses to the fetus in a
concentration 50-
83% of maternal serum. Effects on reproductive capacity and fetal harm are
unknown.
3.5.4 LABORATORY TESTS:
Determinations of heart rate, electrolytes (especially magnesium, potassium
and
calcium) and ECG will be determined (cf Table I) and whenever required in
evaluating
the patient's condition.
Serum digitoxin levels: - Serum digitoxin levels will be determined (cf Study
Calendar)
at two week intervals or if there is a suggestion of digitalis toxicity.
Samples should be
obtained (trough levels) just before the daily dose. The therapeutic
concentration is 10-
35 ng/mL (13-46 nM). However, the steady-state serum concentration should only
be
interpreted in relation to the overall clinical evaluation of the patient. An
isolated serum
concentration value alone will not be used as a basis for increasing or
decreasing the
digitoxin dose.
33
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
B. Description of Study Design and Statistical Analysis
s 4. Methods for Selecting Subjects.
4.1 All patients must have a pathologically verified diagnosis of soft tissue
sarcoma
with histologic, cytologic or clinical evidence of metastatic or locally
advanced
disease (Stage IV or recurrent). Patients with, Kaposi's sarcomas, sarcomas of
bone
or mesotheliomas are not eligible. Please see Staging Criteria, below.
4.2 Patients must have received no more than three prior chemotherapy regimens
for advanced, recurrent or metastatic disease. Prior biologic response
modifier
treatment will be allowed.
4.3 Patients must have unidimensionally measurable lesions by x-ray, scans (CT
or
MRI) or physical examination documented within 28 days prior to registration.
Patients with CNS metastases are not eligible.
4.4 Prior radiation therapy will be allowed. At least 3 weeks must have
elapsed
since the administration of the last fraction of radiation therapy and
patients must
have recovered from all associated toxicities. The measurable disease site
should be
outside of previously irradiated fields.
4.5 Patients must have a Southwest Oncology Group Performance Status of 0 - 2.
4.6 Patients must have either serum creatinine less than 1.5 times the
institutional
upper limit of normal, and serum calcium less than the institutional upper
limit of
normal, and serum potassium within normal limits, obtained within 14 days
prior
to registration.
4.7 Patients with heart disease already on a cardiac glycoside are not
eligible.
4.8 Patients must have adequate hepatic function as defined by a serum
bilirubin.
up to 2.5 x the institutional upper limit of normal (ULN).
4.9 Patients may have received prior surgery. At least 4 weeks must have
elapsed
3o and patients must have recovered from all side-effects associated with
surgery.
4.10 Pregnant or nursing women may not participate. Women/men of reproductive
potential may not participate unless they have agreed to use an effective
contraceptive method.
4.11 Patients may not receive concurrent radiation therapy, hormonal therapy
for
malignancy or other chemotherapy while on this protocol.
4.12 Patients must be physically, mentally and emotionally able to give
informed
consent.
4.13 No other prior malignancy is allowed except for the following: adequately
treated basal cell or squamous cell skin cancer, in situ cervical cancer,
adequately
4o treated Stage I or II cancer from which the patient is currently in
complete
remission, or any other cancer from which the patient has been disease-free
for 5
years.
4.14 If day 14 or 28 falls on a weekend or holiday, the limit may be extended
to the
next working day. In calculating days of tests and measurements, the day a
test or
measurement Is done is considered to be Day 0. Therefore, if a test is done on
a
Monday, the Monday two weeks later would be considered Day 1.
34
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
4.17 Patients must be informed of the investigational nature of this study and
must
sign and give written informed consent in accordance with institutional and
federal
guidelines.
5. Statistical Considerations
5.1. This is a pilot Phase II, non-randomized, single-armed study. The
expected
accrual rate is 5-6 patients per month. The duration of the study is
anticipated to be 12
to months; the duration of each subject's participation is likely to be twelve
to eighteen
months (the approximate duration of time to failure in sarcoma patients
responding to
agents known to be effective). Tumor measurements will be repeated on each
patient at
three to six week intervals.
15 5.2 . A response probability of 20% would be of interest, while further
testing would
not be pursued if the response probability is 5% or lower. Initially, 14
patients will be
entered. If at least one response is observed, an additional 11 patients will
be entered.
or more responses out of 25 will be considered as evidence warranting further
study
of this regimen provided other factors, such as toxicity and survival also
appear
2o favorable. This design has a significance level (probability of falsely
declaring an
agent with a 5% response probability to warrant further study) of 5%, and a
power
(probability of correctly declaring an agent with a 20% response probability
to warrant
further study) of 94%.
True Response Probability 5% 10% 15% 20%
Probability of stopping early 36% 12% 4% 1%
3o Probability of declaring agent 5% 37% 73% 92%
warrants further study
5.3. 25 patients are insufficient to estimate the probability of a particular
toxicity to
within ~ 0.16 (40 patients would be required for this). However, any toxicity
occurnng
with at least 10% probability is likely to be seen at least once (87% chance).
6.0 Description of stud~nrocedures:
6.1 Pretreatment requirements are to be completed as listed on the Study
Calendar,
Section 9Ø
6.2 A baseline CT or MRI scans deemed relevant to tumor evaluation will be
obtained, and repeated at 6 week intervals during treatment.
6.3 Drug Administration: All patients will initially receive the same
treatment.
Digitoxin solution, 0.2 mg will be administered orally twice a day for 4 days.
On day 5
a daily maintenance dose of 0.15 mg will be started. If at six weeks there is
no
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
evidence of digitalis toxicity, the maintenance dose may be increased to 0.20
mg daily.
If after a further six weeks there is no evidence of digitalis toxicity, the
maintenance
dose may be increased to 0.25 mg daily.
6.4 Serum digitoxin levels will be obtained just before daily dose every six
weeks
or whenever there is any suggestion of digitalis toxicity.
6.5 Responding or stable disease patients will continue on study until tumor
progression.
6.6 Criteria For Removal From Protocol Treatment.
a. Progression of disease (as defined in Section 10.1d.5).
1 o b. Delay of treatment greater than 2 weeks.
c. Unacceptable toxicity requiring discontinuation of chemotherapy (ECG
evidence of digitalis toxicity) (see Section 8.0).
6.7 The patient may withdraw from the study at any time for any reason. All
reasons for discontinuation of treatment must be documented in the Flow
Sheets.
6.8 All patients will be followed until death.
6.9 Supportive Therapy, toxicities to be monitored, and dosage modifications:
It is important that the patient ingest an adequate amount of potassium daily.
Foods high in potassium, such a bananas, may be an adequate source.
25
Other Concomitant Medication: No other concomitant medications should be
given except analgesics, chronic treatments for concomitant medical
conditions, or
agents required for life-threatening medical problems. All medications
prescribed
should be checked for drug interactions.
Patient Information:
Avoid over the counter antacids, cough, cold, allergy and diet drugs unless
approved by the investigator(s). Notify physician if loss of appetite, lower
stomach
pain, nausea, vomiting, diarrhea, unusual tiredness or weakness, drowsiness,
headache,
3o blurred or yellow vision, skin rash or hives or mental depression occurs.
7.0 DOSE ADJUSTMENTS: guidelines which follow outline dose adjustments for
several of these toxic effects.
35 IF A PATIENT EXPERIENCES SEVERAL TOXICITIES AND THERE ARE
CONFLICTING RECOMMENDATIONS, PLEASE FOLLOW THE MOST
CONSERVATIVE DOSE ADJUSTMENT RECOMMENDED.
DOSES WHICH HAVE BEEN REDUCED FOR TOXICITY SHOULD NOT BE RE-
4o ESCALATED BACK TO STARTING LEVEL.
7.1 Gastrointestinal: Most common early symptoms are anorexia, nausea,
vomiting
and diarrhea. Abdominal discomfort or pain often accompanies GI symptoms.
Digitalis
toxicity very rarely may cause hemorrhagic necrosis of the intestines.
7.2 CNS: Headaches, weakness, apathy, drowsiness, visual disturbances
(blurred,
yellow vision, halo effect), confusion, restlessness, disorientation,
seizures, EEG
abnormalities, delirium, hallucinations, neuralgia, psychosis.
36
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
7.3 Cardiac disturbances: Ventricular tachycardia may result from digitalis
toxicity.
Unifocal or multiform premature ventricular contractions, especially in
begeminal or
trigeminal patterns, are the most common toxic arrhythmias. Paroxysmal
dysrythmias,
nodal rhythms, AV dissociation, accelerated functional (nodal) rhythm and
paroxysmal
atrial tachycardia with block are also common. Excessive slowing of the pulse
is a
clinical sign of overdose. AV block of increasing degree may proceed to
complete heart
block. Atrial fibrillation can occur following large doses of digitalis.
Ventricular
fibrillation is the most common cause of death from digitalis poisoning. The
ECG is
to essential in determining the presence and nature of these cardiac
disturbances.
7.4 Hypokalemia: Administer potassium chloride intravneouslty or in divided
oral
doses.
7.5 Digitoxin will be held if there is evidence of cardiac toxicity. The
decision to
reduce the dose or discontinue therapy with digitoxin will be made in
conjunction with
a cardiac consultant.
7.6 Unexpected or fatal toxicities (including suspected reactions) must be
reported
to the Operations Office, to the Study Coordinator, and to the IRB.
8.0 CRITERIA FOR EVALUATION AND ENDPOINT DEFINITIONS
Definitions:
a. Measurable Disease: Unidimensionally measurable lesions with clearly
defined margins by: 1) medical photograph (skin or oral lesion), or plain x-
ray with at
least one diameter .5 cm or greater (bone lesions are not included) or, 2) CT,
MRI or
3o other imaging scan with at least two diameters greater than the distance
between cuts
of the imaging study, or 3) palpation with 2 diameters 2 cm or greater,
although only
one diameter selected initially need be measured.
b. Evaluable Disease: Masses with margins not clearly defined, lesions with
both
diameters less than 0.5 cm, lesions on scan with either diameter smaller than
the
distance between cuts, palpable lesions with either diameter less than 2 cm,
bone
disease.
c. Non-Evaluable Disease: Pleural effusions, ascites, disease documented by
4o indirect evidence only (e.g., by lab values).
d. Objective Status, To Be Recorded at Each Evaluation: If an organ has too
many measurable lesions to measure at each evaluation, choose three to be
followed
before the patient is entered on study. The remaining measurable lesions in
that organ
will be considered evaluable for the purpose of objective status
determination. Unless
progression is observed, objective status can only be determined when ALL
measurable
and evaluable sites and lesions are assessed.
37
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
8.1 Complete Response (CR): Complete disappearance of all measurable and
evaluable disease. No new lesions. No disease related symptoms. No evidence of
non-evaluable disease, including normalization of markers and other abnormal
lab
values. All measurable, evaluable and non-evaluable lesions and sites must be
assessed
using the same techniques as baseline. Refers to clinical CR--when restaging
surgery is
required, a separate pathologic response variable is incorporated in the
response data.
8.2 Partial Response (PR): Applies only to patients with at least one
measurable
lesion: Greater than or equal to 50% decrease under baseline in the sum of
products of
1o perpendicular diameters of all measurable lesions. No progression of
evaluable
disease. No new lesions. All measurable and evaluable lesions and sites must
be
assessed using the same techniques as baseline.
8.3 Partial Response, Non-Measurable (PRNM): Not applicable.
8.4. Stable/No Response: Does not qualify for CR, PR, or progression. All
measurable and evaluable sites must be assessed using the same techniques as
baseline.
8.5. Progression: 50% increase or an increase of 10 cm2 (whichever is smaller)
in
2o the sum of products of all measurable lesions over smallest sum observed
(over
baseline if no decrease) using the same techniques as baseline, OR clear
worsening of
any evaluable disease, OR reappearance of any lesion which had disappeared, OR
appearance of any new lesion/site, OR failure to return for evaluation due to
death or
deteriorating condition (unless clearly unrelated to this cancer). For "scan
only" bone
disease, increased uptake does not constitute clear worsening. Worsening of
existing
non-evaluable disease does not constitute progression.
8.6 Exceptions: (1) In cases for which initial tumor flare reaction is
possible
(hypercalcemia, increased bone pain, erythema of skin lesions), either
symptoms must
3o persist beyond four weeks or there must be additional evidence of
progression. (2)
Lesions which appear to increase in size due to presence of necrotic tissue
will not be
considered to have progressed.
8.7. Unknown: Progression has not been documented and one or more measurable
or evaluable sites have not been assessed.
8.8 Notes:
4o a. Non-evaluable disease does not affect objective status except in
determination
of CR (must be absent - a patient who otherwise has a CR, but who has non-
evaluable
disease present or not assessed, will be classified as having a PR), and in
determination
of progression (if NEW sites of non-evaluable disease develop). Patients with
only
non-evaluable disease cannot be assessed for response.
b. For evaluable disease other than types specified in Section 10.1d.3, the
only
objective statuses which apply are CR, stable/no response, progression and
unknown.
38
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
c. Objective statuses must stay the same or improve over time until
progression
(unknown excepted).
d. PR and PRNM cannot apply to the same patient.
e. Best Response: This will be calculated from the sequence of objective
statuses.
For patients with all disease sites assessed every three to six weeks, two
objective status determinations of CR before progression are required for a
best
response of CR. Two determinations of PR or better before progression, but not
qualifying for a CR, are required for a best response of PR. Two
determinations of
stable/no response or better before progression, but not qualifying as CR, PR
or PRNM,
are required for a best response of stable/no response; if the first objective
status is
unknown, only one such determination is required. Patients with an objective
status of
progression on or before the second evaluation (second AFTER the prestudy
evaluation) will have a best response of increasing disease. Best response is
unknown
if the patient does not qualify for a best response of increasing disease and
if all
objective status determinations after the first determination and before
progression are
unknown.
For patients with disease scheduled to be assessed only at greater than six
week
intervals, only one assessment of stable/no response or better before
progression, but
not qualifying for a CR, PR or PRNM is required for a best response of
stable/no
response. For CR, PR or PRNM response must be confirmed; a second assessment
should be scheduled for four weeks after the first documentation of response.
Patients
with objective status of progression at the first evaluation will have a best
response of
increasing disease. Best response is unknown if the patient does not qualify
for best
response of increasing disease and all objective status determinations before
3o progression are unknown.
f. Performance Status: Patients will be graded according to the current
Southwest
Oncology Group grading scale:
GRADE SCALE
0 Fully active; able to carry on all predisease activities without
restriction.
1 Restricted in physically strenuous activity but ambulatory and able to
4o carry out work of a light or sedentary nature, e.g., light housework,
office work.
2 Ambulatory and capable of all self care but unable to carry out any work
activities. Up and about more than 50% of waking hours.
3 Capable of only limited self care; confined to bed or chair more than 50%
of waking hours.
39
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
4 Completely disabled. Cannot carry on any self care. Totally confined to
bed or chair.
Dead
5
g. Time to Treatment Failure: From date of registration to date of first
observation
of progressive disease (as defined in 10.1d.5), death due to any cause, or
early
discontinuation of treatment.
h. Time to Death: From date of registration to date of death due to any cause.
9.0 BIBLIOGRAPHY.
1. Boring CC, Squires TS, Tong T. Cancer statistics CA 41:19-39, 1991.
2. Yan JC, Glatstein E, Rosenberg SA, Antman DH. Sarcomas of soft tissues, in:
2o Cancer: Principles & Practice of Oncoiogy, Fourth Edition. DeVita VT, Jr.~
Heilman
S, Rosenberg SA (eds). JB Lippincott, Philadelphia, 1436-1488, 1993.
3. Borden EC Arnato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH,
Lerner H-I, Carbone PP. Randomized comparison of three Adriamycin regimens for
metastatic soft tissue sarcomas. J Clin Onc 5:84050, 1987.
4. Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT,
Zaino
RJ. A randomized study of Adriamycin with and withoutdimethytriazenoimidazole
carboxamide in advanced uterine sarcoma. Cancer 52:62632, 1983.
35
5. Edmonson JH, Ryan LM, Blum RH, Brooks JSJ, Shiraki M, Frytak S, Parkinson
DR.
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin
or
mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J
Clin
Onc 11:1269-1275, 1993.
6. Amman K, Crowley J, Balcerzak SP, et al. An intergroup Phase Ill randomized
study
of doxorubicin and dacarbazine with or without ifosfamide and mesna in
advanced
soft tissue and bone sarcomas. J Clin Onc 11:1271285, 1993.
7. Repke KRH, Schon R, Megges R et al. Potential suitability of Na+/K+ -
transporting
ATPase in pre-screens for anti-cancer agents. Anti-Cancer Drugs Design 10:177-
187, 1995.
8. Gheorghiade M, Pitt B. Digitalis Investigation Group (DIG) trial: A
stimulus for
further research. Am Heart J 134:3-12, 1997.
9. Garg R, Gorlin R, Smith T et al. The effect of digoxin on mortality and
morbidity
inpatients with heart failure. N Engl J Med 336:525-533, 1997.
8. Hyun J-W, Shin J-E, Lim K-H et al. Evomonoside: The cytotoxic cardiac
glycoside
from Lepidium apetalum. Planta Med 61:294-295, 1995.
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
9. Inada A, Nakanishi T, Konoshima T, et al. Anti-tumor promoting activities
of
natural products. II. Inhibitory effects of digitoxin on two-stage
carcinogenesis of
mouse skin tumors and mouse pulmonary tumors. Biol. Pharm. Bull 16:930-931,
1993.
10. Stenkvist B, Bengtsson E, Eriksson O et al. Cardiac glycosides and breast
cancer.
Lancet Mar 10; 1 (8115):563, 1979.
11. Stenkvist B, Bengtsson E, Eklund G et al. Evidence of a modifying
influence of
1o heart glucosides on the development of breast cancer. Analytical and
Quantitative
Cytology 2:49-54, 1980.
12. Stenkvist B, Bengtsson E, Dahlqvist B et al. Cardiac glycosides and breast
cancer,
revisited. N Engl J Med 306:484.
13. Goldin AG, Safa AR. Digitalis and Cancer. Lancet May 19; 1(8386):1134,
1984.
14. Friedman GD. Digitalis and Breast Cancer. Lancet Oct 13; 2(8407):875,
1984.
17. Stenkvist B. Is digitalis a therapy for breast carcinoma: Oncol Rep 6:493-
496,
1999.
41
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
Example 6. A PHASE II TRIAL OF CP 4071 IN PATIENTS WITH RECURRENT
EPITHELIAL MULLERIANADENOCARCINOMA
I. OBJECTIVES
A. To determine response rate and toxicity of CP4071 in patients with
recurrent
epithelial mullerian cancer.
B. To assess the clinical and laboratory toxicities of this dose/schedule of
CP4071.
1 o II. BACKGROUND AND RATIONALE
In 1999, it is estimated that there will be 25,200 cases of ovarian cancer
diagnosed in the United States (1). The majority of these patients present
with advanced
stage epithelial neoplasms where the management includes aggressive
cytoreductive
surgery and cytotoxic chemotherapy. Despite innovative surgical strategies and
multi-
agent chemotherapy, patients will experience recurrence of the ovarian cancer.
Previous studies by the Gynecologic Oncology Group established the
superiority of cisplatin and paclitaxel over cisplatin and cyclophosphamide
for the
2o initial treatment of advanced stage epithelial ovarian cancer (2).
Subsequent
investigators demonstrated that carboplatin/paclitaxel is equivalent to
cisplatin/paclitaxel when treating these patients (3). Despite prolongation of
median
progression free and overall survival, many of these patients will experience
recurrent
disease. Though many therapeutic options are available for recurrent disease,
there is
no consensus as to the optimal regimen. One must consider efficacy, toxicity,
route of
administration and cost when deciding how to treat each individual patient.
There
definitely is a need for more effective and less toxic treatment for patients
with
recurrent ovarian carcinoma.
3o STUDY RATIONALE
Both in vitro and epidemiological data suggest that the cardiac glycosides
have
antitumor activity. Since the benefits and safety of digitoxin administration
are well
known in humans, it is appropriate to determine if doses routinely used to
treat patients
with cardiac disorders are sufficient to achieve an antitumor effect in
patients with
recurrent mullerian epithelial adenocarcinoma.
III. EXPERIMENTAL PLAN
A. Study Design
1. Phase II
2. Digitoxin
3. Non-randomized
4. Multicenter
5. No stratification
6. Endpoints:
a) Maximum tolerated
dose
b) Efficacy
42
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
c) Toxicity
Number of patients: 40
Estimated study duration: 12 months
IV. PATIENT ELIGIBILITY AND ENROLLMENT
A. Inclusion
Criteria.
1. Patients must have been previously treated
at least once
with a platinum analogue and paclitaxel
prior to entry.
2. Patients with a histologic diagnosis
of recurrent ovarian,
tubal, or peritoneal cancer or a CA 125
>100 in patients
who have a history of ovarian, tubal
or peritoneal cancer.
3. Patients must have received no more than
three prior
chemotherapy regimens for advanced, recurrent
or
metastatic disease. Prior biologic response
modifier
treatment will be allowed.
4. Patients must have bidimensionally measurable
lesions by
x-ray, scans (CT or MRI), physical examination
documented within 28 days prior to registration.
Patients
with CNS metastases are not eligible.
Alternatively,
patients with serum CA125 levels over
100 with no
measurable disease may be enrolled in
this study.
5. Prior radiation therapy will be allowed.
At least 3 weeks
must have elapsed since the administration
of the last
fraction of radiation therapy and patients
must have
recovered from all associated toxicities.
The measurable
disease site should be outside of previously
irradiated
fields.
6. Adequate bone marrow, renal and hepatic
function as
3o defined by WBC greater than 3,000 cells/cu.ml.,
platelets
greater than or equal to 100,000/cuml.,
creatinine less than
1.5 mg/dl, total bilirubin less than
or equal to 2 mg/dl,
AST/ALT/alkaline phosphatase level <two
times the
upper limit of normal in the absence
of liver metastasis or
<five times the upper limit of normal
if liver metastasis
was present.
7. Gynecologic Oncology Group (GOG) performance status
less than or equal to 2 (see Appendix I).
8. Patients who have signed an approved informed consent.
B. Exclusion Criteria
1. Patients with epithelial ovarian cancer of low malignancy
potential.
2. Patients with septicemia, severe infection, or acute
hepatitis.
3. Patients with severe gastrointestinal bleeding.
4. Patients with a past or concomitant malignancy other than
43
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
skin (excluding melanoma).
5. Patients with heart disease already on a cardiac glycoside
are not eligible.
6. Patients with known cardiac disease, not already on a
cardiac glycoside, may be enrolled unless they have
idiopathic hypertrophic stenosis.
7. Patients with hypokalemia are not eligible until serum
potassium level is within the normal range.
8. Pregnant or nursing women may not participate. Women
l0 of reproductive potential may not participate unless they
have agreed to a pregnancy test and to use an effective
contraceptive method.
Following determination of eligibility and acquisition of signed
informed consent, patients are deemed eligible for protocol entry.
Patients will be followed by their gynecologic oncologist to assess
efficacy of the medication with regards to their ovarian cancer. Cardiologists
will follow the patients digitoxin levels, ECG's, and assess patients for
2o evidence of digitoxin toxicity.
V. CRITERIA FOR EVALUATION AND ENDPOINT
DEFINITIONS
A. Definitions.
1. Measurable Disease: Bidimensionally measurable lesions
with clearly defined margins by 1 ) medical photograph
(skin or oral lesion) or plain x-ray with at least one
diameter 0.5 cm or greater (bone lesions are not included),
or 2) CT, MRI or other imaging scan with both diameters
greater than the distance between cuts of the imaging
study, 3) palpation with both diameters 2 cm or greater, or
4) CA 125 greater than 100.
2. Evaluable Disease: Unidimensionally measurable lesions,
masses with margins not clearly defined, lesions with both
diameters less than 0.5 cm, lesions on scan with either
diameter smaller than the distance between cuts, palpable
lesions with either diameter less than 2 cm, bone disease.
3. Non-Evaluable Disease: Pleural effusions, ascites.
4. Complete Response (CR): A clinical complete response
requires the complete disappearance of all known
measurable and evaluable disease determined by two
measurements not less than four weeks apart. A serologic
complete response will be defined by the decline of the
44
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
previously elevated CA 125 declined to within normal
limits on two successive measurements three weeks apart.
Refers to clinical CR--when restaging surgery is required,
a separate pathologic response variable is incorporated in
the response data.
5. Partial Response: A clinical partial response will be
defined by greater than 50% decrease in the sum of the
products of the greatest length and perpendicular width of
1 o all measurable lesions for at least four weeks, with no
simultaneous increase in evaluable disease during this
period. A serologic partial response will be defined by a
50% decrease in the previously elevated CA 125 which is
confirmed on repeat analysis 3 weeks later. All
measurable and evaluable lesions and sites must be
assessed using the same techniques as baseline.
6. Stable Disease: State of response that is less than partial
response or progression and lasts for at least eight weeks
2o with no clinical evidence of progression.
7. Progression: 50% increase or an increase of 10 cmz
(whichever is smaller) in the sum of products of all
measurable lesions over smallest sum observed (over
baseline if no decrease) using the same techniques as
baseline, OR clear worsening of any evaluable disease,
OR reappearance of any lesion which had disappeared,
OR appearance of any new lesion/site, OR failure to return
for evaluation due to death or deteriorating condition
(unless clearly unrelated to this cancer) OR doubling of
CA 125 which is confirmed on repeat analysis three weeks
later. For "scan only" bone disease, increased uptake does
not constitute clear worsening. Worsening of existing
non-evaluable disease does not constitute progression.
8. Unknown: Progression has not been documented and one
or more measurable or evaluable sites have not been
assessed.
4o Exceptions:
(1) In cases for which initial tumor flare reaction is possible
(hypercalcemia, increased bone pain, erythema of skin lesions), either
symptoms must persist beyond four weeks or there must be additional
evidence of progression. (2) Lesions which appear to increase in size due to
presence of necrotic tissue will not be considered to have progressed.
Notes:
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
a. Objective Status, To Be Recorded at Each Evaluation: If an organ has too
many measurable lesions to measure at each evaluation, choose three to
be followed before the patient is entered on study. The remaining
measurable lesions in that organ will be considered evaluable for the
purpose of objective status determination. Unless progression is
observed, objective status can only be determined when ALL measurable
and evaluable sites and lesions are assessed.
b. Non-evaluable disease does not affect objective status except in
to determination of CR (must be absent - a patient who otherwise has a CR, but
who has non-evaluable disease present or not assessed, will be classified as
having a PR), and in determination of progression (if NEW sites of non-
evaluable disease develop). Patients with only non-evaluable disease cannot
be assessed for response.
c. For evaluable disease other than types specified in Section V.A., the only
objective statuses which apply are CR, stable/no response, progression and
unknown.
d. Objective statuses must stay the same or improve over time until
progression (unknown excepted).
e. PR and PRNM cannot apply to the same patient.
f. Best Response: This will be calculated from the sequence of objective
statuses.
For patients with all disease sites assessed every three to six weeks, two
objective status determinations of CR before progression are required for a
best response of CR. Two determinations of PR or better before progression,
but not qualifying for a CR, are required for a best response of PR. Two
determinations of stable/no response or better before progression, but not
qualifying as CR, PR or PRNM, are required for a best response of stable/no
response; if the first objective status is unknown, only one such
determination is required. Patients with an objective status of progression on
or before the second evaluation (second AFTER the pre-study evaluation)
will have a best response of increasing disease. Best response is unknown if
the patient does not qualify for a best response of increasing disease and if
all
objective status determinations after the first determination and before
progression are unknown.
For patients with disease scheduled to be assessed only at greater than six
week intervals, only one assessment of stable/no response or better before
progression, but not qualifying for a CR, PR or PRNM is required for a best
response of stable/no response. For CR, PR or PRNM response must be
confirmed; a second assessment should be scheduled for four weeks after the
first documentation of response. Patients with objective status of progression
at the first evaluation will have a best response of increasing disease. Best
46
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
response is unknown if the patient does not qualify for best response of
increasing disease and all objective status determinations before progression
are unknown.
g. Time to Treatment Failure: From date of registration to date of first
observation of progressive disease (as defined in 10.1d.5), death due to any
cause, or early discontinuation of treatment.
VI. STUDY DRUG
See Example 5.
A. Pharmacokinetics: See Example 5
I5 B. Toxicity: See Example 5
C. Precautions
1. Electrolyte imbalance:
a) Potassium - See Example 5. Potassium chloride
in divided oral doses of 3-6 gm (40-80 mEq) daily
may be given if renal function is adequate. Do not use
potassium when severe or complete heart block is due
to digitalis.
Calcium - See Example 5.
c) Magnesium - Hypomagnesemia may predispose to
digitalis toxicity. If low magnesium levels are
detected, institute replacement therapy.
D. Laboratory Tests:
1. Periodic determinations of heart rate, electrolytes
3o (especially potassium and calcium) and ECG will be
determined (Table 1 ) and whenever required in evaluating
the patient's condition.
2. Serum digitoxin levels: - Serum digitoxin levels will be
determined. Samples should be obtained (trough levels)
just before the daily dose. The therapeutic concentration is
10-35 ng/mL (13-46 nM). However, the steady-state
serum concentration should only be interpreted in the
overall clinical evaluation of the patient. Do not use an
isolated serum concentration value alone as a basis for
4o increasing or decreasing the digitoxin dose.
E. Drug Interactions: See Example 5
F. Contraindications: See Example S
1. A previous toxic response to digitalis preparations,
ventricular fibrillation, pregnancy, ventricular tachycardia,
beriberi heart disease, allergy to digitalis, although rare
may occur and some cases of hypersensitive carotid sinus
syndrome.
47
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
2. Pregnancy: See Example 5.
3. Concomitant medications: See Example 5.
VII. STUDY PROCEDURES
A. If anytime during study a tissue sample is obtained, a portion will
be stored frozen at -70°C for possible determination of tissue
digitoxin levels and an additional portion stored at 4°C for
chemosensitivity testing.
B. The patient may withdraw from the study at any time for any
1 o reason.
C. All reasons for discontinuation of treatment must be documented
in the Flow Sheets.
D. The development of any evidence of cardiac toxicity will result in
a discontinuation of digitoxin. The decision to reduce the dose or
15 discontinue therapy with digitoxin will be made in conjunction with a
cardiac consultant if necessary.
E. Serum digitoxin levels will be obtained just before the daily dose
every four weeks or whenever any suggestion of digitalis toxicity.
F. Other Concomitant Medication: No other concomitant
2o medications should be given except analgesics, chronic treatments for
concomitant medical conditions, or agents required for life-
threatening medical problems. Before prescribing any concomitant
medication, review VLF. (Drug Interactions).
VIII. STUDY DESIGN and STATISTICAL ANALYSIS
A. If day 14 or 28 falls on a weekend or holiday, the limit may be
extended to the next working day and is considered to be Day 0.
Therefore, if a test is done on a Monday, the Monday two weeks later
would be considered Day 14.
B. Patients must be informed of the investigational nature of this
study and must sign and give written informed consent in accordance
with institutional and federal guidelines. .
IX.DOSAGE DETERMINATION
A. Eligible patients initially will be slowly digitalized, with 4 ml (0.2
mg) digitoxin twice daily for 4 days, followed by a maintenance
dosage of 1 ml (0.05) to 6 ml (0.3 mg). The initial maintenance dose
will be O.lSmg daily. If after four weeks at 3m1 (0.15 mg) daily
4o there is no evidence of digitalis toxicity (ECG, digitoxin blood level,
GI or visual symptoms, the maintenance dose may be increased to 4
ml (0.2 mg) daily. If after four weeks at 4 ml (0.2 mg) daily there is
no evidence of digitalis toxicity (ECG, digitoxin blood level, GI or
visual symptoms), the maintenance dose may be increased to 5 ml
(0.25 mg) daily. All patients must start at the 3 ml (0.15 mg) digitoxin
dose and may be escalated to the 5 ml (0.25 mg) dose if tolerated in
the above schedule.
48
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
B. If a patient experiences a Grade 3 or Grade 4 arrhythmia, the
digitoxin dose will be withheld. Once resolved, the patient may be
restarted at the next lower non cardiotoxic dose.
X. EFFICACY DETERMINATION
A. Response Rate: That proportion of patients who responded to
treatment with complete response or partial response.
to B. Response Duration: The time from the initial documented
response to the first sign of disease progression.
C. Time to Progression: The time from initial administration of
study medication to documented disease progression.
D. Time to Response: The time from the first infusion of study
15 medication to the time of initial documented response.
E. Survival: The time from the first dose of study medication until
death due to any cause.
25
XI. LABORATORY STUDIES
A. Pretreatment laboratory studies included a complete blood count,
electrolytes, BUN, creatinine, glucose, total protein, albumin, calcium,
phosphate, uric acid, alkaline phosphatase, total and direct bilirubin,
ALT, AST and amylase.
XII. ADVERSE EVENTS
A. Definitions:
1. Serious adverse event: any experience that is fatal or life-
threatening, requires or extends inpatient hospitalization, or is a
congenital anomaly, or important medical observation.
2. Associated with the use of the drug: there is a reasonable possibility
that the experience may have been caused by the drug.
3. Unexpected adverse event: any adverse event that is not identified
in nature, severity, or frequency in the current investigators brochure
or package insert.
4. Gradin : Toxicities and their standard grading, based on
World Health Organization (WHO) criteria, are given in
4o Appendix Ill. Adverse events which are not included in
the WHO scale will be graded accordingly;
0 = none
1 = mild
2 = moderate
3 = severe
4 = life threatening or debilitating
5 = fatal
49
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
B. Reporting:
1. Adverse events will be reported as required by section 312.32 of the
Code of Federal Regulations.
2. CellPath, Inc. will be provided with a copy of all serious adverse
event reports filed with the FDA.
XIII. STATISTICAL CONSIDERATIONS
to A. All patients will be followed until disease progression or until
death.
B. This is a pilot Phase II, non-randomized, single-armed study. The
expected accrual rate is S-6 patients per month. The duration of the
study is anticipated to be 12 months; the duration of each subject's
participation is likely to be twelve to eighteen months (the
approximate duration of time to failure in ovarian cancer patients
responding to agents known to be effective). Tumor measurements
will be repeated on each patient at three to six week intervals.
C. A response probability of 20% would be of interest, while further
2o testing would not be pursued if the response probability is 5% or
lower. Initially, 14 patients will be entered. If at least one response is
observed, an additional 11 patients will be entered. 5 or more
responses out of 25 will be considered as evidence warranting further
study of this regimen provided other factors, such as toxicity and
survival also appear favorable. This design has a significance level
(probability of falsely declaring an agent with a 5% response
probability to warrant further study) of 5%, and a power (probability
of correctly declaring an agent with a 20% response probability to
warrant further study) of 94%.
True Response Probability 5% 10% 15% 20%
Probability of stopping early 36% 12% 4% 1%
Probability of declaring agent S% 37% 73% 92%
warrants further study
D. 25 patients are insufficient to estimate the probability of a
particular toxicity to within ~ 0.16 (40 patients would be required for
this). However, any toxicity occurnng with at least 10% probability
is likely to be seen at least once (87% chance).
E. Kaplan-Meier survival statistics may be performed.
REFERENCES
1. Landis S et al. Cancer Statistics. Cancer J Clin 49:8-24, 1999.
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
2. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and
cisplatin compared with paclitaxel and cisplatin in patients with stage III
and stage IV ovaraian cancer. N Engl J Med 334:1-6, 1996.
3. Ozols RF, Bundy BN, Fowler J et al. Randomized Phase III Study of
Cisplatin (CIS/Paclitaxel (PAC) Versus Carboplatin ((CARBO)/PAC in
Optimal Stage III Epthelial Ovarian Cancer (0C): A Gynecolog9ic
Oncology Group Trial. (Proc ASCO Abstract 1373) J Clin Oncol
18:356a, 1999.
4. Repke KRH, Schon R, Megges R et al. Potential suitability of Na+/K+ _
transporting ATPase in pre-screens for anti-cancer agents. Anti-Cancer
Drugs Design 10:177-187, 1995.
5. Hyun J-W, Shin J-E, Lim K-H et al. Evomonoside: The cytotoxic
cardiac glycoside from Lepidium apetalum. Planta Med 61:294-295,
1995.
6. Inada A, Nakanishi T, Konoshima T, et al. Anti-tumor promoting
2o activities of natural products. II. Inhibitory effects of digitoxin on two-
stage carcinogenesis of mouse skin tumors and mouse pulmonary tumors.
Biol. Pharm. Bull 16:930-931, 1993.
7. Stenkvist B, Bengtsson E, Eriksson O et al. Cardiac glycosides and
breast cancer. Lancet Mar 10; 1(8115):563, 1979.
8. Stenkvist B, Bengtsson E, Eklund G et al. Evidence of a modifying
influence of heart glucosides on the development of breast cancer.
Analytical and Quantitative Cytology 2:49-54, 1980.
9. Stenkvist B, Bengtsson E, Dahlqvist B et al. Cardiac glycosides and
breast cancer, revisited. N Engl J Med 306:484, 1982.
10. Goldin AG, Safa AR. Digitalis and Cancer. Lancet May 19;
3s 1(8386):1134, 1984.
11. Friedman GD. Digitalis and Breast Cancer. Lancet Oct 13; 2(8407):875,
1984.
12. Stenkvist B. Is digitalis a therapy for breast carcinoma: Oncol Rep
6:493-496, 1999.
13. Gheorghiade M, Pitt B. Digitalis Investigation Group (DIG) trial: A
stimulus for further research. Am Heart J 134:3-12, 1997.
14. Garg R, Gorlin R, Smith T et al. The effect of digoxin on mortality and
morbidity inpatients with heart failure. N Engl J Med 336:525-533, 1997.
51
CA 02362917 2001-08-13
WO 00/47215 PCT/US00/03564
APPENDIX I
Performance Status: Patients will be graded according to the current
Gynecology Oncology Group grading scale:
GRADESCALE
0 Fully active; able to carry on all pre-disease activities without
restriction.
1 Restricted in physically strenuous activity but ambulatory and
able to carry out work of a light or sedentary nature, e.g., light
housework, office work.
2 Ambulatory and capable of all self care but unable to carry
out any work activities. Up and about more than 50% of waking
hours.
3 Capable of only limited self care; confined to bed or chair
more than 50% of waking hours.
4 Completely disabled. Cannot carry on any self care. Totally
confined to bed or chair.
5 Dead
It is to be understood that the invention is not to be limited to the exact
details
of operation, or to the exact compounds, compositions, methods, procedures or
3o embodiments shown and described, as obvious modifications and equivalents
will be
apparent to one skilled in the art, and the invention is therefore to be
limited only by the
full scope of the appended claims.
52
